Corporate Profile
Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZM™ chemistry technology platform in an effort to develop Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). These novel compounds are being designed to treat inherited RNA nonsense mutations and ribosomal mutations in cancers. Eloxx also has clinical stage and early and late-stage preclinical programs for the treatment of inherited RNA nonsense mutations in various rare diseases. The company also has earlier stage discovery programs evaluating its compounds for the treatment of a subset of mutationally driven cancers.